Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack
Salas-Benito D (1,2), Melero I (2,3,4), Ponz-Sarvise M (5,4,6).
No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.See related article by Le et al., p. 5493.
CITATION Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. doi: 10.1158/1078-0432.CCR-19-1753. Epub 2019 Jul 17